Jennison Associates
XLRN

Jennison Associates’s Acceleron Pharma XLRN Stock Holding History

Jennison Associates’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-30,041
Closed -$767K – 826
2016
Q4 		$767K Buy
+30,041
New +$952K ﹤0.01% 635
2014
Q4 		– Sell
-49,863
Closed -$1.51M – 771
2014
Q3 		$1.51M Buy
49,863
+75
+0.2% +$2.11K ﹤0.01% 610
2014
Q2 		$1.69M Sell
49,788
-5,765
-10% -$193K ﹤0.01% 584
2014
Q1 		$1.92M Buy
55,553
+187
+0.3% +$8.44K ﹤0.01% 593
2013
Q4 		$2.19M Buy
+55,366
New +$1.34M ﹤0.01% 558

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return